Drug-labels.com

Nduvra: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
1 %
Active ingredient:
ATC code:

Patient Medication Information: uses, side effects, how to take - Nduvra

What NDUVRA is used for:

NDUVRA is a cream used on the skin to treat:

  • Plaque psoriasis in adults; and
  • Moderate to severe atopic dermatitis (eczema) in adults and children 2 years of age and older.

How NDUVRA works:

Plaque psoriasis is a skin condition that causes areas of inflamed skin where skin cells grow too fast. This creates red, scaly, thick patches (plaques) of skin. NDUVRA works to control your psoriasis by reducing inflammation (redness, swelling, itching, thickness, flaking).

Atopic dermatitis (eczema), is a skin condition that causes inflammation, itching, and redness in areas of the skin. NDUVRA works to treat your atopic dermatitis by reducing inflammation.

The ingredients in NDUVRA are:

Medicinal ingredients: tapinarof

Non-medicinal ingredients: benzoic acid, butylated hydroxytoluene, citric acid monohydrate, diethylene glycol monoethyl ether, disodium edetate, emulsifying wax, medium-chain triglycerides, polyoxyl 2 stearyl ether, polyoxyl 20 stearyl ether, polysorbate 80, propylene glycol, purified water, and sodium citrate dihydrate.

NDUVRA comes in the following dosage forms:

Cream; tapinarof 1% w/w

Do not use NDUVRA if:

  • If you are allergic to tapinarof or any of the other ingredients found in NDUVRA, or any parts of the container (see The ingredients in NDUVRA are).

To help avoid side effects and ensure proper use, talk to your healthcare professional before you apply NDUVRA. Talk about any health conditions or problems you may have, including if you:

  • are pregnant or plan to become pregnant. It is not known if NDUVRA can harm your unborn baby.

  • are breastfeeding or plan to breastfeed. It is not known if NDUVRA passes into your breast milk. Talk to your healthcare professional about the best way to feed your baby during treatment with NDUVRA.

Other warnings you should know about:

Severe allergic skin reactions: You may experience a severe skin reaction (itchy rash, red spots or patches, blisters, fluid-filled bumps, etc.), when treated with NDUVRA. The reaction may start at the application site and progress to other areas of the skin. If you notice you are having a skin reaction to NDUVRA, talk to a healthcare professional right away.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Drug interactions have not been studied for NDUVRA.

How to apply NDUVRA:

  • Use NDUVRA exactly as your healthcare professional tells you to use it.
  • NDUVRA is for external use only. NDUVRA is NOT for oral, ophthalmic, or intravaginal use.
  • Apply NDUVRA to dry, clean skin.
  • Only apply NDUVRA to areas of the skin with psoriasis or atopic dermatitis (eczema).
  • Do not apply NDUVRA to any areas of the skin with an active infection.
  • Wash your hands after applying NDUVRA unless you are using it to treat your hands. If someone else is applying NDUVRA for you, they should wash their hands after applying it on you.
  • Avoid swimming, bathing, showering, or difficult activities for at least 2 hours after applying NDUVRA.
  • Wait for 30 minutes after applying NDUVRA, before applying any other creams, ointments, lotions or oils.

Usual dose:

Apply a thin layer of NDUVRA, only to parts of your skin with psoriasis or atopic dermatitis (eczema), once a day.

If you apply too much NDUVRA, wipe some of it off.

Overdose:

Missed Dose:

If you forget to use NDUVRA use it as soon as you remember. Do NOT use NDUVRA more than once a day.

Possible side effects from using NDUVRA:

These are not all the possible side effects you may have when using NDUVRA. If you experience any side effects not listed here, tell your healthcare professional.

If you think you, or a person you are caring for, have taken any NDUVRA orally, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Serious side effects and what to do about them

Frequency/Side Effect/SymptomTalk to your healthcare professionalStop using drug and get immediate medical help
Only if severeIn all cases
VERY COMMON
Folliculitis: red raised bumps around hair pores
COMMON
Nasopharyngitis: pain or swelling in the nose and throat
Contact Dermatitis: skin rash or irritation including itching and redness, peeling, burning, or stinging
Headache
Influenza (flu): fever, cough, muscle and body aches, headache, runny or stuffy nose, sore throat, sinus congestion, sneezing, generally feeling unwell
Pruritus (Itching)
RARE
Urticaria: hives

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store between 2°C and 25°C.

Do not freeze.

Protect from exposure to excessive heat.

Keep out of reach and sight of children.

If you want more information about NDUVRA:

  • Talk to your healthcare professional.
  • Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada Drug Product Database website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html; the manufacturer’s website www.organon.ca, or by calling 1-844-820-5468.

Date of Authorization: 2026-08-20

® Dermavant Sciences GmbH. Used under license.

© 2026 Organon group of compagnies. All rights reserved.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02448254

Approved according to the text: August 20, 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Nduvra

Rx or OTC
Prescription (Rx)?
DIN 02448254
Schedule(s) PRESCRIPTION
Active ingredient(s) Tapinarof 1 %
Dosage form(s) Cream
Route(s) of administration Topical
Drug class (WHO ATC)
  1. D Dermatologicals
    1. D05 Antipsoriatics
      1. D05A Antipsoriatics for topical use
        1. D05AX Other antipsoriatics for topical use
          1. D05AX07 Tapinarof
Company ORGANON CANADA INC.
Current status Marketed
Current status date September 25, 2025

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.